title: Cardiovascular disease and its relationship with chronic kidney disease.
abstract: Cardiovascular disease (CVD), the leading cause of death, is mostly precipitated by cardiometabolic risk and chronic kidney disease (CKD). CVD and kidney disease are closely interrelated and disease of one organ cause dysfunction of the other, ultimately leading to the failure of both organs. Patients with end-stage renal disease (ESRD) are at much higher risk of mortality due to CVD. Traditional CVD risk factors viz., hypertension, hyperlipidemia, and diabetes do not account for the high cardiovascular risk in CKD patients and also standard clinical interventions for managing CVD that are successful in the general population, are ineffective to lower the death rate in CKD patients. Nontraditional factors, related to disturbed mineral and vitamin D metabolism were able to provide some explanation in terms of vascular calcification, for the increased risk of CVD in CKD. Fibroblast Growth Factor 23, a bone-derived hormone that regulates vitamin D synthesis in renal proximal tubules and renal phosphate reabsorption, has been suggested to be the missing link between CKD and CVD. Acute Kidney Injury (AKI) is strongly related to the progress of CVD and its early diagnosis and treatment has significant positive effect on the outcomes of CVD in the affected patients. Besides this, non-dialysable protein-bound uraemic toxins such as indoxyl sulfate and p-cresyl sulfate, produced by colonic microbes from dietary amino acids, appear to cause renal dysfunction. Thus, therapeutic approaches targeting colonic microbiota, have led to new prospects in early intervention for CKD patients. Intervention targets for preventing CVD events in CKD patients ideally should include control of blood pressure and dyslipidemia, diabetes mellitus, lowering proteinuria, correction of anemia, management of mineral metabolism abnormalities and life style changes including smoking cessation, decreased consumption of salt, and achievement of normal body mass index. Use of β-blockers, renin-angiotensin blockers, diuretics, statins, and aspirin are helpful in the early stages of CKD. In this review, we will address the biological, pathological and clinical relationship between CVD and CKD and their therapeutic management.
authors.affiliation: Graduate School, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. mwlj521@163.com.
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: X-C
authors.initials: XC
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: Y
authors.initials: Y
authors.lastname: Cao
authors.forename: R-R
authors.initials: RR
authors.lastname: Sun
authors.forename: S
authors.initials: S
authors.lastname: Chen
authors.forename: P-Y
authors.initials: PY
authors.lastname: Zhang
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006973:Hypertension / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011507:Proteinuria / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D012307:Risk Factors; D040242:Risk Reduction Behavior
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin